Mural Oncology Grants Inducement Options and Restricted Stock Units to Newly Hired Employees
DUBLIN, Ireland March 04, 2024 - Mural Oncology plc (Nasdaq: MURA), a renowned clinical-stage immuno-oncology company specializing in immune cell modulation and protein engineering, has recently made an important announcement regarding inducement grants under Nasdaq Listing Rule 5635(c)(4).On March 1, the company granted non-statutory stock options and restricted stock units to two newly hired employees.These grants were made in accordance with the Company’s 2024 Inducement Stock Option and Incentive Plan and were crucial in attracting and retaining talented individuals in their workforce.
Mural Oncology’s innovative approach to immuno-oncology revolves around developing novel engineered cytokine therapies with the aim of addressing unmet needs in cancer patients.By leveraging their core competencies in immune cell modulation and protein engineering, the company seeks to offer groundbreaking solutions that can transform cancer treatment.
Under the recent grants, the two new employees have been awarded non-statutory stock options entitling them to purchase a total of 4,225 ordinary shares of the Company.Additionally, they have also received restricted stock units with respect to an aggregate of 2,275 ordinary shares of the Company.These inducement grants play a vital role in attracting and incentivizing top talent in the competitive field of oncology research and development.
The inducement grants were made as part of Nasdaq Listing Rule 5635(c)(4), which allows public companies to offer equity incentives to newly hired employees.By utilizing this rule, Mural Oncology has availed itself of a valuable tool in enhancing its recruitment efforts, especially in attracting highly qualified professionals that can contribute to their mission of revolutionizing cancer treatment.
Mural Oncology’s commitment to developing cutting-edge therapies is evident in their focus on immune cell modulation and protein engineering.The company’s 2024 Inducement Stock Option and Incentive Plan provides them with the flexibility to offer competitive equity packages to bring in top talent.This approach ensures that Mural Oncology is well-positioned to achieve its goal of addressing unmet needs in cancer treatment and making a lasting impact in the lives of patients.
At the time of this announcement, Mural Oncology had 16.689733 million shares outstanding, with each share valued at $5.39.The inducement grants mark a significant event as the company grows its workforce and strengthens its capabilities in immuno-oncology research and development.
In conclusion, Mural Oncology plc’s recent press release highlights the company’s commitment to attracting and retaining top talent through inducement grants under Nasdaq Listing Rule 5635(c)(4).By offering non-statutory stock options and restricted stock units, Mural Oncology aims to incentivize and reward new employees for their contributions to the advancement of their innovative cytokine therapies.These grants not only showcase the company’s dedication to revolutionizing cancer treatment but also position them as a leader in the field of immuno-oncology.
Comments